LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

11.94 -4.33

Buy Sell

Overview

Share price change

24h

Current

Min

11.4

Max

12.48

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	4.857 51.415
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+59.87% upside

Market Stats
By TradingEconomics
Market Cap	2.2B
Previous open	16.27
Previous close	11.94

News Sentiment

By Acuity

10%

90%

7 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 maj 2026, 23:10 UTC

Hot Stocks

Stocks to Watch: Agilysys, XP

18 maj 2026, 18:44 UTC

Major Market Movers

Claritev Shares Recover After Comments About DOJ

18 maj 2026, 23:55 UTC

Earnings

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 maj 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 maj 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 maj 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 maj 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 maj 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

18 maj 2026, 20:25 UTC

Earnings

Correct: XP 1Q Total Client Assets BRL1.53T

18 maj 2026, 20:23 UTC

Earnings

XP 1Q Total Client Assets BRL1.53B

18 maj 2026, 20:19 UTC

Earnings

XP 1Q Adj EPS BRL2.49 >XP

18 maj 2026, 20:19 UTC

Earnings

XP 1Q Rev BRL4.73B >XP

18 maj 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 maj 2026, 19:00 UTC

Earnings

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 maj 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 maj 2026, 18:17 UTC

Market Talk

Acquisitions, Mergers, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 maj 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 maj 2026, 16:57 UTC

Acquisitions, Mergers, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 maj 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 maj 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 maj 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 maj 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 maj 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 maj 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 maj 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Vinci Buys Canada's Modern Group of Companies

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

59.87% upside

12 Months Forecast

Average 20 USD 59.87%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

7 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.